Double w/o/w self-nano emulsifying drug delivery system of imatinib mesylate for colon cancer treatment

Abstract

The aim of the research was to prepare & evaluate double w/o/w self-nano emulsifying drug delivery system (SNEDDS) of imatinib mesylate (IMT) and to investigates its anticancer activity against MDST8 human colon carcinoma cell lines. The self-nano emulsifying drug delivery system was prepared by the aqueous phase titration method. After the necessary screening, the optimized formulation (F-SEN-5) was characterized for surface morphology, using high-resolution transmission electron microscopy (Philips CM 120 BioTwin, U.S.A.). Furthermore, average droplet diameter (Δdm), polydispersity index (PDI), refractive index (Ri), viscosity (η), percentage transmittance (%T), percentage drug content (% DC), In-vitro drug release studies were measured for all the formulations; The optimized F-SEN-5 shows R2 = 0.9987, n (0.5 < n < 1.0) = 0.732, indicating the Korsmeyer-Peppas drug release model and anomalous transport. The higher drug release profile (99.42 ± 5.23%) at 60 min, higher transmittance (%) (98.56 ± 0.56%), low viscosity (28.67 ± 3.67cps), low PDI (0.078 ± 0.05), low average droplet diameter (47.56 ± 5.78 nm) at 2:1 Smix ratio. The in-vitro cytotoxicity (%) and IC50 value of F-SEN-5 while treating MDST8 human colon carcinoma cell lines were found to be 93.71 ± 8.11% and 15 µM. The formulation provides an additional 20% more efficiency than the free IMT drug. Overall, these findings suggested that double w/o/w nanoemulsions can be successfully used for SNEDDS of IMT for chemoprevention of colon cancer.